UB Paderborn / Katalog / Suche / in CDI

1 – 20 von 20

Sortiert nach

General clinical and methodological considerations on the extrapolation of pharmacokinetics and optimization of study protocols for small molecules and monoclonal antibodies in children

British journal of clinical pharmacology, 2022-12, Vol.88 (12), p.4985-4996

2022

Volltextzugriff (PDF)

CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis

The pharmacogenomics journal, 2020-04, Vol.20 (2), p.306-319

2020

Volltextzugriff (PDF)

Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events

Frontiers in genetics, 2022-09, Vol.13, p.982955-982955

2022

Volltextzugriff (PDF)

Warfarin dose prediction in children using pharmacogenetics information

British journal of haematology, 2012-10, Vol.159 (1), p.106-109

2012

Volltextzugriff (PDF)

Characterizing variability in warfarin dose requirements in children using modelling and simulation

British journal of clinical pharmacology, 2014-07, Vol.78 (1), p.158-169

2014

Volltextzugriff (PDF)

Is Trough Concentration of Vancomycin Predictive of the Area Under the Curve? A Commentary

Therapeutic drug monitoring, 2017-06, Vol.39 (3), p.303

2017

Volltextzugriff (PDF)

Pharmacogenetics-based warfarin dosing in children

Pharmacogenomics, 2014-02, Vol.15 (3), p.361-374

2014

Volltextzugriff (PDF)

A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children

BMC medical informatics and decision making, 2015-02, Vol.15 (1), p.7-7, Article 7

2015

Volltextzugriff (PDF)

Warfarin dose prediction in children using pharmacometric bridging—comparison with published pharmacogenetic dosing algorithms

European journal of clinical pharmacology, 2013-06, Vol.69 (6), p.1275-1283

2013

Volltextzugriff (PDF)

A Proposal for an Individualized Pharmacogenetics-Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy

Clinical pharmacology and therapeutics, 2011-11, Vol.90 (5), p.701-706

2011

Volltextzugriff (PDF)

A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age

Clinical pharmacology and therapeutics, 2010-06, Vol.87 (6), p.727-734

2010

Volltextzugriff (PDF)

A PK–PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy

Clinical pharmacology and therapeutics, 2007-04, Vol.81 (4), p.529-538

2007

Volltextzugriff (PDF)

Effect of CYP2C9, VKORC1, and CYP4F2 on warfarin maintenance dose in children aged less than 18 year of age: systematic review and meta-analysis

Clinical pharmacology and therapeutics, 2018, Vol.103 (S1), p.S52

2018

Volltextzugriff (PDF)

Erratum to: Warfarin dose prediction in children using pharmacometric bridging – comparison with published pharmacogenetic dosing algorithms

European journal of clinical pharmacology, 2013, Vol.69 (9), p.1737-1737

2013

Volltextzugriff (PDF)

Pharmacometric models for individualisation of warfarin in adults and children

Hamberg, Anna-Karin

2013

Volltextzugriff (PDF)

Antiretroviral treatment of HIV infection: Swedish recommendations 2005

Scandinavian journal of infectious diseases, 2006, Vol.38 (2), p.86-103

2006

Volltextzugriff (PDF)

Scaling Dose-Exposure-Response from Adults to Children

Fundamentals of Pediatric Drug Dosing, 2016, p.93-107

2016

Volltextzugriff (PDF)

Selective inhibition of prostaglandin D2 biosynthesis in human mast cells to overcome need for multiple receptor antagonists: Biochemical consequences

Clinical and experimental allergy, 2021-04, Vol.51 (4), p.594-603

2021

Volltextzugriff (PDF)

Eosinophils synthesize trihydroxyoctadecenoic acids (TriHOMEs) via a 15-lipoxygenase dependent process

Biochimica et biophysica acta. Molecular and cell biology of lipids, 2020-04, Vol.1865 (4), p.158611-158611, Article 158611

2020

Volltextzugriff (PDF)

Selective inhibition of prostaglandin D 2 biosynthesis in human mast cells to overcome need for multiple receptor antagonists: Biochemical consequences

Clinical and experimental allergy, 2021-04, Vol.51 (4), p.594-603

2021

Volltextzugriff (PDF)

1 – 20 von 20

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(17)
Mit Volltextzugriff
(18)

Publikationsform

Sprache

Englisch
(20)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(15)
Science & Technology
(15)
Humans
(13)
Pharmacology & Pharmacy
(9)
Warfarin - Administration & Dosage
(8)
Anticoagulants - Administration & Dosage
(7)
Child
(7)
Adolescent
(6)
Female
(6)
Male
(6)
Medicin Och Hälsovetenskap
(6)
Warfarin
(6)
Adult
(5)
Aryl Hydrocarbon Hydroxylases - Genetics
(5)
Cytochrome P-450 Cyp2c9
(5)
Pharmacogenetics
(5)
Biological And Medical Sciences
(4)
Children
(4)
Genotype
(4)
Medical Sciences
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

General clinical and methodological considerations on the extrapolation of pharmacokinetics and optimization of study protocols for small molecules and monoclonal antibodies in children

CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis

Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events

Warfarin dose prediction in children using pharmacogenetics information

Characterizing variability in warfarin dose requirements in children using modelling and simulation

Is Trough Concentration of Vancomycin Predictive of the Area Under the Curve? A Commentary

Pharmacogenetics-based warfarin dosing in children

A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children

Warfarin dose prediction in children using pharmacometric bridging—comparison with published pharmacogenetic dosing algorithms

A Proposal for an Individualized Pharmacogenetics-Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy

A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age

A PK–PD Model for Predicting the Impact of Age, CYP2C9, and VKORC1 Genotype on Individualization of Warfarin Therapy

Effect of CYP2C9, VKORC1, and CYP4F2 on warfarin maintenance dose in children aged less than 18 year of age: systematic review and meta-analysis

Erratum to: Warfarin dose prediction in children using pharmacometric bridging – comparison with published pharmacogenetic dosing algorithms

Pharmacometric models for individualisation of warfarin in adults and children

Antiretroviral treatment of HIV infection: Swedish recommendations 2005

Scaling Dose-Exposure-Response from Adults to Children

Selective inhibition of prostaglandin D2 biosynthesis in human mast cells to overcome need for multiple receptor antagonists: Biochemical consequences

Eosinophils synthesize trihydroxyoctadecenoic acids (TriHOMEs) via a 15-lipoxygenase dependent process

Selective inhibition of prostaglandin D 2 biosynthesis in human mast cells to overcome need for multiple receptor antagonists: Biochemical consequences

Suchergebnisse filtern